Current Clinical Trials

  • ORTHOPEDICS: LIBERATE

    LIBERATE is a randomized controlled clinical trial comparing use of bupivacaine with the adjuncts dexamethasone and epinephrine to liposomal bupivacaine in interscalene nerve block for shoulder arthroplasty patients.

  • CARDIO: Heart Failure - PROACTIVE-HF TRIAL

    Dr. Jason Gluck is participating in this trial collecting information which will provide clinicians with a better understanding of the Cordella PA Sensor System as a potential solution for proactive Heart Failure management, early detection of fluid overload and possibly the prevention of worsening Heart Failure symptoms.

  • CARDIO: Heart Failure - At Home-HF Pilot

    Dr. Radojevic and the Heart Failure Team are participating in this trial to evaluate the efficacy and safety of the Furoscix Infusor versus continued medical therapy in patients with chronic heart failure and fluid overload.

  • CARDIO: Heart Failure - DAPA TIMI 68

    Dr. Jaiswal and Hartford Hospital’s Heart Failure Department are enrolling patients in this international trial for patients with heart failure and reduced ejection fraction who will be randomized to dapagliflozin versus placebo while in the hospital.

  • CANCER: Genomic Profiling IMPACT (MSK 12-245)

    The purpose of this genomic profiling study is to determine whether certain genes in cancer may be abnormal.

  • CANCER: HEME MSK 16-024 Leukemia Registry

    Observational Study to Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

  • CARDIO: Heart Failure - GUIDE-HF

    Under the direction of Dr. Haronian, the Heart Failure Team is participating in the CardioMEMs Heart Failure System which is currently the only FDA approved system for previously hospitalized NYHC III heart failure patients.

  • CARDIO: Heart Failure - ANTHEM-HFrEF Pivotal Study

    Dr. Joseph Radojevic is the Principal Investigator of the ANTHEM Trial which will try to determine whether Autonomic Regulation Therapy (ART) in addition to medical therapy is safe and more effective than medical therapy alone for the treatment of heart failure.

  • CANCER: Pancreatic Cancer Tyme-88-PANC

    A Phase II Multi-Center Study of SM-88 in Patients with Pancreatic Cancer Whose Disease Has Progressed or Recurred after/on First Line Chemotherapy.

  • CARDIO: HeartFailure - PARAGLIDE-HF

    Dr. Jaiswal and the Heart Failure Team will participate in this study investigating certain blood tests that may help identify patients that are at increased risk of death or re-hospitalized again after discharge. This blood test will reflect elevated pressures or stress on the heart to help identify patients at higher risk.

  • CANCER: Lung Cancer E4512

    This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK).

  • CANCER: Lung Cancer AO81105

    This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery.

  • CARDIO: Electrophysiology - ACUTUS

    Dr. Tolat and the Department of Electrophysiology are participating in this study is to demonstrate if the AcQBlate Force Sensing System is safe and effective when used to ablate the cavotricuspid isthmus (CTI) for the treatment of typical atrial flutter when compared to a literature-based control. The System is designed for electrophysiologic (EP) mapping and RF ablation of atrial flutter.

  • CARDIO: Electrophysiology - Discover-US

    AcQMap US Registry is an observational, prospective, multi-center, open-label registry designed to provide clinical outcomes data regarding the commercial, real-life experience with the diagnostic AcQMap System being conducted by Dr. Tolat and the Department of Electrophysiology.

  • CANCER: Pancreatic Cancer MSK 19-239

    A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

  • CARDIO: Electrophysiology - LEADR

    Dr. Meir Friedman is the Principal Investigator for this trial. The Next Generation ICD Lead is indicated for the treatment of subjects who have experienced, or are at significant risk of developing, life-threatening ventricular tachyarrhythmias. The purpose of this study is to assess the safety and efficacy of the Next Generation ICD Lead.

  • CANCER: Breast Cancer NRG BR005

    This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy destroyed the breast cancer cells and may be compared to the tumor removed during surgery to check if they are the same.

  • The COVID-19 and Cancer Consortium (CCC19) Registry

    In late 2019 and early 2020, the world witnessed the outbreak of respiratory disease caused by a novel coronavirus first detected in Wuhan, China, and now a pandemic. The virus has been named SARS-CoV-2, and the disease it causes, coronavirus disease 2019, abbreviated as COVID-19. There are now over 300,000 persons diagnosed with this disease around the world, and nearly 14,000 deaths.

  • CARDIO: Electrophysiology - VANISH-2

    Under the direction of Eric Crespo, MD and the Electrophysiology Department, this study will determine whether catheter ablation or antiarrhythmic drug therapy provides the most effective control of important clinical outcomes for patients with prior myocardial infarction and sustained monomorphic ventricular tachycardia.

  • PSYCH: Neural Architecture of Social Emotional Processing and Regulation in Autism Spectrum Disorder

    This study delineates the temporal dynamics of the neural networks underlying social behaviors and emotional processing in relation to the diagnosis of autism spectrum disorder (ASD) and its social traits.

  • CANCER: Leukemia D8220C00008 (Heme)

    A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia.

  • PSYCH: Major Depressive Disorder - ESKETINSUI2002 (Janssen)

    Clinical trial to examine the efficacy and safety of an investigational medication - esketamine (given as a nasal spray) - in adolescents hospitalized with depression and suicidal ideation.

  • CARDIO: Electrophysiology - The Arm Aflutter Study

    Dr. Aneesh Tolat is the Principal Investigator for this trial evaluating the safety, feasibility, and efficacy of performing typical atrial flutter ablation through the arm.

  • CARDIO: Structural - APOLLO

    Dr. Talhat Azemi in conjunction with the Structural Heart Team are participating in this international trial evaluating the safety and efficacy of the Medtronic Intrepid TMVR system in patients with moderate to severe or severe symptomatic mitral regurgitation who are unable to have standard transcatheter or surgical repair.

  • CANCER: Bladder/Urothelial Cancer A031701 (GU)

    This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

  • PSYCH: Post-Traumatic Stress Disorder - 331-201-00071 (Otsuka)

    Clinical trial to examine the efficacy and safety of brexpriprazole combined with sertraline as treatment for adults with posttraumatic stress disorder.

  • CANCER: Thoracic Cancer LUNGMAP

    This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400).

  • CARDIO: Structural - RESTORE

    RESTORE is a multi-center, non-randomized trial designed to evaluate the safety and effectiveness of the HARPOON Beating Heart Mitral Valve Repair System in patients with severe degenerative mitral regurgitation (DMR).

  • PSYCH: Major Depressive Disorder 1402-0011 (Boehringer-Ingelheim)

    Clinical trial to examine the efficacy and safety of an investigational medication compound compared to placebo in patients with Major Depressive Disorder.

  • CARDIO: Structural - CORCINCH-HF

    This study is a randomized trial to evaluate the safety and effectiveness of the AccuCinch Ventricular Restoration System and compare it to standardized heart failure medication.

  • CANCER: Thoracic Cancer S1900B

    This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

  • PSYCH: Obsessive Compulsive Disorder (OCD) BHV4157-303

    Clinical trial to investigate the efficacy of troriluzole as an adjunctive therapy when added to standard of care to evaluate safety and tolerability of the investigational medication in obsessive compulsive disorder.

  • CANCER: RadOnc MSK 18-359

    Drugs called checkpoint inhibitors help the immune system fight cancer. When the effectiveness of these drugs wears off, it may be possible to renew their effectiveness by combining it with a special type of radiation therapy called stereotactic body radiation therapy (SBRT).

  • CARDIO: Vascular - SSB 11-02

    The primary objective of the study is to determine whether the GORE® TAG® Thoracic Branch Endoprosthesis (TBE device) is safe and effective in treating thoracic aortic pathologies.

  • CARDIO: Vascular - CREST-2

    Dr. Parth Shah and the Vascular Surgery Team will be participating in this two-parallel multi-centered, randomized, observer-blinded endpoint clinical trial. One trial will assess treatment differences between intensive medical management alone compared to carotid endarterectomy with intensive medical management. The parallel trial will assess treatment differences between intensive medical management alone compared to carotid artery stenting plus intensive medical management.

  • CANCER: Endometrial Cancer MSK 20-067

    This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.

  • CANCER: Ovarian Cancer NRG-CC008

    This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations.

  • CARDIO: Vascular - CREST-H

    Dr. Shah in conjunction with the Vascular Surgical team will participate in this trial to determine whether patients with cerebral hemodynamic impairment and mild cognitive impairment benefit from carotid revascularization.

  • CARDIO: Cardiac Surgery - PROACT Xa

    This is a prospective, multicenter, open-label, randomized active controlled clinical trial to determine if apixaban is non-inferior to warfarin (INR target range 2.0 - 3.0) for the primary composite outcome of valve thrombosis and valve-related thromboembolism in patients with an On-X mechanical heart valve implanted in the aortic position.

  • CANCER: Radiation Oncology MSK 18-486

    This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

  • CARDIO: Cardiac Surgery - ON-X Post Approval Clinical Registry Study

    Dr. Robert Hagberg and the Cardiac Surgical Team will evaluate the On-X aortic valve performance in normal general open practice using a new lower anticoagulant (blood thinner) dose approved and recommended by the United States Food and Drug Administration (FDA) in 2015.

  • CANCER: Gynecologic Cancer NRG-GY006

    This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer.

  • CARDIO: Cardiac Surgery - PERIGON

    The purpose of this trial is to evaluate the safety and effectivenss of the Medtronic Model 400 aortic valve bioprosthesis in a patient undergoing surgical aortic valve replacement of a native aortic valve, or replacement of a failed prosthesis.

  • CANCER: Neurologic Cancer EF-32/ TRIDENT

    To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.

  • CANCER: Endometrial Cancer NRG GY018

    This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent).

  • CARDIO: Cardiac Surgery - Terminate AF Study

    The purpose of the clinical study is to evaluate the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices to expand the Indication for use to include the treatment of persistent atrial fibrillation and long-standing persistent atrial fibrillation (non-paroxysmal AF) in subjects undergoing concomitant cardiac surgery.

  • CARDIO: TAVR - PROTECTED TAVR

    This study hopes to demonstrate that use of the Sentinel Cerebral Protection System significantly reduces the risk of peri-procedural stroke <72 hours after transcatheter aortic valve replacement (TAVR).

  • CANCER: Liver Cancer SRN-705-005 (Phase 1)

    This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma or liver metastasis in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy.

  • CANCER: Multiple Tumor Types NRG-GY022

    This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer.

  • CARDIO: Cardiac Catheterization - STEMI DTU

    This trial hopes to demonstrate that left ventricular unloading with Impella and a 30 minute delay to reperfusion when compared with immediate PCI will show a reduction in infarct size and heart failure related clinical events.

  • CARDIO: Cardiac Catheterization - Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa

    People who have had a heart attack can have another heart attack and stroke in the future. The test being researched is a blood test that is designed to guide personalized treatment designed to prevent those events.

  • CANCER: Breast Cancer EA1181

    This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy.

  • CANCER: Bladder Cancer MSK 19-374

    This study will test the safety of BCG and gemcitabine in people who have BCG-relapsing Non-Muscle Invasive Bladder Cancer (NMIBC). The researchers will test increasing doses of gemcitabine to find the highest dose that causes few or mild side effects when combined with BCG.

  • CARDIO: Preventive Cardiology - The Horizon Study

    The Horizon Study is a randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with known cardiovascular disease.

  • CARDIO: Preventive Cardiology - The CASCADE FH Registry

    CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia is being conducted under the direction of Dr. Paul Thompson and Preventive Cardiology.

  • CANCER: Kidney Cancer MK6482-012

    The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).

  • CARDIO: Electrophysiology – Jewel IDE Study

    Dr. Zweibel and the Electrophysiology team will study the clinical evaluation of the Jewel P-WCD , a patch-wearable Cardioverter Defibrillator in patients who are at high risk for sudden cardiac arrest.

  • CANCER: Thoracic Cancer MSK 18-541

    The purpose of this registry study is to actively monitor people with GGOs and collect information about them, so that investigators can learn more about these lesions and about the risk of developing lung cancer in study participants whose GGOs are being monitored in the active surveillance program.

  • CANCER: Bladder Cancer S1806

    This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer.

  • CANCER: Colorectal Cancer A221805

    This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer.

  • CANCER: Breast Cancer NRG-BR004

    This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic).

  • CANCER: Ovarian Cancer AVB500-OC-004/ GOG-3059

    This is a randomize, double-blind Phase 3 study to compare the efficacy and safety of AVB-S6-500 in combination with paclitaxel (Pac) versus placebo in combination with Pac in patients with platinum resistant recurrent ovarian cancer.

  • CANCER: Thoracic Cancer S1900E

    This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.

  • CANCER: Colon Cancer NRG-GI005

    This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery.

  • CANCER: Multiple Tumor Types 9801-CL-0101

    The purpose of this study is to assess the safety and tolerability of ASP9801 and to determine the recommended phase 2 dose (RP2D).

  • CANCER: Biospecimen s15-­01162

    This is a non-­interventional multicenter human research study in which we hope to better understand genetic and epigenetic changes that take place in T cells in Cutaneous T-­cell lymphoma (CTCL).

  • CANCER: Multiple Tumor Types TAPUR

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

  • CANCER: Breast Cancer A011801

    This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer.

  • CANCER: Thoracic Cancer MSK 20-415

    The purpose of this study is to find out whether treatment with the study drug durvalumab combined with a type of radiation therapy called stereotactic body radiation (SBRT) is a more effective treatment for early-stage non-small cell lung cancer (NSCLC) than SBRT alone.

  • PSYCH: Children of Parents with Alzheimer's Needed for Research on Brain Structure/Function

    Children of parents with alzheimer's are needed for research on brain structure/function. To be eligible individuals must be between the ages of 40 and 60, have a mother or father diagnosed with dementia/Alzheimer's after age 60, not be currently exercising, be willing to exercise 3 times per week for 6 months at Hartford Hospital, and be willing to undergo an MRI scan.

  • PSYCH: Healthy Volunteers Needed for Neuroimaging (Brain Scan) Study

    Investigators at The Anxiety Disorders Center at the Institute of Living/Hartford Hospital are recruiting participants without psychiatric problems for a neuroimaging (brain scan) study. We are offering a study that involves undergoing a neuroimaging (brain) scan while also participating in tasks that will examine your brain functioning.

  • PSYCH: Participants Needed for Sickle Cell/Brain fMRI Research Study

    This research study intends to understand how pain affects the brains of people with sickle cell disease. Healthy volunteers who are African-American and between the ages of 15-30 years are eligible. One 3-hour visit will be required and you will be compensated for your time!

  • PSYCH: Researchers seeking adolescents with and without ADHD, ages 9-18

    The Olin Neuropsychiatry Research Center at The Institute of Living is conducting a study of adolescents with ADHD ages 9-18 and healthy adolescents ages 9-18 to look at how the brain functions during decision-making in cognitive tasks. The study will require at least 1 visit to complete interviews with clinical staff and MRI scans. Qualified volunteers will be compensated $20 per hour for participation.

  • PSYCH: Researchers Seeking Adults with Autism Spectrum Disorders, Ages 18-40

    The Olin Neuropsychiatry Research Center at The IOL is conducting a study of adults with autism spectrum disorders (ASD) ages 18-40 to look at how our brains process social interactions and how it is different in individuals with ASD. The study may require two or more visits to complete interviews with clinical staff, MRI scans and an EEG. Qualified volunteers are compensated $20/hour for their time.

  • PSYCH: Healthy Adults Sought For Research Study

    The Olin Neuropsychiatry Research Center at The Institute of Living is looking for healthy adults 18-60 with no significant history of mental illness. Participation will include: interviews and questionnaires, pencil and computer games, and an MRI. Qualifying persons will be compensated $20 per hour for their time. Lunch provided.

  • PSYCH: Participants with a Family History of Alcoholism Needed for Research Study

    Are you a healthy, right-handed adult between the ages of 18 and 35? You may qualify to participate in a research study at The Olin Neuropsychiatry Research Center at the IOL. Individuals matching that description who have relatives with alcoholism or a history of alcoholism are eligible to participate in this research study.

  • PSYCH: Help for Hoarding at No Cost

    The Anxiety Disorders Center at the Institute of Living/Hartford Hospital is conducting a study for people with Hoarding Disorder.

  • PSYCH: Healthy Volunteers Needed for Research Study

    The Anxiety Disorders Center at the Institute of Living/Hartford Hospital is recruiting participants with no current or lifetime history of psychiatric problems for a research study.

  • CANCER: Lung Cancer Alchemist A151216

    This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been, or will be removed by surgery.

  • CANCER: Yoga 4 Cancer

    If you are a patient at the Hartford HealthCare Cancer Institute at Hartford Hospital, or a patient with a musculoskeletal condition and a cancer history being seen through the Hartford HealthCare Bone & Joint Institute, you may be eligible for a research study investigating the benefits of yoga on mobility and quality of life.

MSK_ClinicalTrials_Ad